| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084954789 |
| P356 | DOI | 10.1038/SREP46557 |
| P932 | PMC publication ID | 5402285 |
| P698 | PubMed publication ID | 28436427 |
| P50 | author | Soumya Swaminathan | Q21062285 |
| Manickam Ashokkumar | Q58851311 | ||
| P2093 | author name string | Luke Elizabeth Hanna | |
| V D Ramanathan | |||
| Narayanaiah Cheedarla | |||
| Padmapriyadarsini Chandrasekaran | |||
| Viswanath Buddolla | |||
| Jagadish Chandrabose Sundaramurthi | |||
| K Lucia Precilla | |||
| Nandagopal Kailasam | |||
| S Kalyanaraman Vaniambadi | |||
| Hemalatha Babu | |||
| K K Vidya Vijayan | |||
| P2860 | cites work | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 |
| Immune correlates of vaccine protection against HIV-1 acquisition | Q26778573 | ||
| Structural insights on the role of antibodies in HIV-1 vaccine and therapy | Q26829461 | ||
| HIV‐1 neutralizing antibodies: understanding nature's pathways | Q27000480 | ||
| Virological features associated with the development of broadly neutralizing antibodies to HIV-1 | Q27025177 | ||
| HIV broadly neutralizing antibody targets | Q27026662 | ||
| Viral membrane fusion | Q27486639 | ||
| A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies | Q27655865 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral theraphy | Q83518445 | ||
| Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption | Q37624842 | ||
| Lessons learned from HIV vaccine clinical efficacy trials | Q37724091 | ||
| Antibody Epitope Exposure and Neutralization of HIV-1 | Q37815513 | ||
| Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response | Q38707583 | ||
| Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies | Q39400103 | ||
| Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays | Q39988991 | ||
| Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design | Q40679052 | ||
| In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire | Q41602128 | ||
| Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. | Q43646588 | ||
| Murine monoclonal antibodies directed against the transmembrane protein gp41 of human immunodeficiency virus type 1 enhance its infectivity | Q45872928 | ||
| Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning | Q46683819 | ||
| Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans | Q27678062 | ||
| Topology of the C-Terminal Tail of HIV-1 gp41: Differential Exposure of the Kennedy Epitope on Cell and Viral Membranes | Q28476449 | ||
| Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India | Q28483205 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection | Q33504604 | ||
| Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables | Q33614495 | ||
| Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection | Q33702217 | ||
| HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies | Q33753573 | ||
| Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | Q33798076 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. | Q34178201 | ||
| Anti-idiotypic antibody vaccine for type B viral hepatitis in chimpanzees | Q34196582 | ||
| Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface | Q34473958 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate | Q35580892 | ||
| Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual | Q35592911 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design | Q35868076 | ||
| Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort | Q35894094 | ||
| Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection | Q35974269 | ||
| The development of CD4 binding site antibodies during HIV-1 infection | Q36155396 | ||
| Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop | Q36694111 | ||
| Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. | Q36961578 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 | Q37171251 | ||
| B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates | Q37171260 | ||
| Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India | Q37179996 | ||
| Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding | Q37240035 | ||
| HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies | Q37293480 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 46557 | |
| P577 | publication date | 2017-04-24 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals | |
| P478 | volume | 7 |
| Q55359818 | Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. |
| Q89609089 | Innovations in HIV-1 Vaccine Design |
| Q57452585 | Mapping of neutralizing antibody epitopes on the envelope of viruses obtained from plasma samples exhibiting broad cross-clade neutralization potential against HIV-1 |
| Q92561961 | The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes |
Search more.